WO2000078946A2 - Treatment of viral influenza with antisense oligonucleotides - Google Patents
Treatment of viral influenza with antisense oligonucleotides Download PDFInfo
- Publication number
- WO2000078946A2 WO2000078946A2 PCT/US2000/016810 US0016810W WO0078946A2 WO 2000078946 A2 WO2000078946 A2 WO 2000078946A2 US 0016810 W US0016810 W US 0016810W WO 0078946 A2 WO0078946 A2 WO 0078946A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- influenza
- nitric oxide
- antisense oligonucleotide
- inos
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Definitions
- Viral influenza can develop despite appropriate vaccination. Once infected, ensuing morbidity and mortality is greatest among high-risk populations, such as the very old or young, those with chronic disease, and the immunocompromised population. There are relatively few available compounds that have significant anti-viral activity against influenza.
- amantadine and rimantadine are the only drugs available that have a proven efficacy in diminishing viral influenza-induced morbidity after infection. Both drugs work by blocking the influenza M2 protein ion channel. Their impact has been limited by under-utilization, a lack of activity against influenza B, the rapid development of viral resistance to the drugs, and adverse effects.
- zanamivir GG167
- GS4104 the ethyl ester prodrug of GS4071
- Most studies of zanamivir have involved topical administration by inhalation of dry powder aerosols and/or intranasal doses of aqueous solutions. These routes rapidly provide high local concentrations at the sites of delivery.
- GS4104 is administered orally, which allows for greater ease of administration, and probably more uniform distribution of the active compound in the respiratory tract.
- Zanamivir treatment has been shown to reduce the severity and duration of naturally occurring, uncomplicated influenza illness in adults. In some instances, however, these drugs are ineffective and are limited in their use. This is in part because they must be administered within 48 hours post-infection to provide benefit. Unfortunately, many patients fail to present to their health provider until they have been infected for over 48 hours. Such late clinical presentation largely ablates any hope for a therapeutic effect in these patients, who may go on to develop severe morbidity or death. Accordingly, a therapy to diminish viral influenza induced morbidity and mortality that can be administered later than 48 hours post-infection is needed.
- Viral influenza pulmonary pathology is due to a variety of factors, and among the most important is the induction of inducible nitric oxide synthase (iNOS) activity, and the subsequent production of the radical, nitric oxide (NO). Three isoforms of the nitric oxide synthase (NOS) have been cloned.
- iNOS inducible nitric oxide synthase
- nitric oxide synthase Two of the isoforms, endothelial and neuronal NOS, are generally expressed constitutively and are Ca 2+ and calmodulin dependent. These constitutive forms of nitric oxide synthase are associated with the physiologic functions of NO in a healthy host.
- the other isoform of nitric oxide synthase is expressed by transcriptional induction and is thus called inducible nitric oxide synthase (iNOS).
- iNOS inducible nitric oxide synthase
- iNOS produces nitric oxide in response to inflammation and infection.
- the inducible form of nitric oxide synthase has been found to be present in activated macrophages and is induced in endothelial cells and vascular smooth muscle cells by various cytokines and/or microbial products.
- the iNOS antisense inhibitor may be administered directly to the lung tissue throughout and beyond the duration of a viral influenza infection. It is a further object of this invention to provide compositions that include antisense oligonucleotides that inhibit inducible nitric oxide synthase and can be administered directly to the lungs.
- Another object of this invention is to provide a combination treatment for viral influenza using an antisense oligonucleotide iNOS inhibitor and specific antiviral agents active against viral influenza or other respiratory pathogens, with or without additional anti-inflammatory agents. It is a further object of the invention to provide compositions of inducible nitric oxide synthase antisense oligonucleotides inhibitors in a suitable pharmaceutical vehicle for delivery into the lungs. Such compositions may also include antiviral and anti-inflammatory agents.
- One aspect of this invention is a method of treatment of viral influenza in a patient in need of said treatment, comprising administering to the patient an antisense oligonucleotide that specifically hybridizes to mRNA transcribed by a gene that encodes inducible nitric oxide synthase, such that synthesis of inducible nitric oxide synthase is inhibited in the patient.
- an antisense oligonucleotides that may be used with the current invention is the following:
- the antisense oligonucleotides of the present invention may have modified nucleotides and/or modifications to the phosphate backbone, such as wherein at least one phosphate bond groups comprises phosphorothioate or alkylphosphonate.
- the antisense oligonucleotides are preferably delivered to the lungs in a pharmaceutically acceptable carrier such as a cationic lipid in a nebulized or aerosolized form.
- Another aspect of this invention is a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically effective amount of at least one antisense oligonucleotide that specifically hybridizes to mRNA transcribed by the gene encoding inducible nitric oxide synthase, and inhibits the synthesis of inducible nitric oxide synthase, and a pharmaceutically acceptable vehicle that can deliver said at least one antisense oligonucleotide to the lungs.
- This composition may be combine with at least one drug for the treatment of viral influenza.
- the present invention provides a therapy for treating viral influenza by inhibiting the synthesis of inducible nitric oxide synthase (iNOS).
- iNOS inducible nitric oxide synthase
- the invention is based on the use of antisense oligonucleotides that hybridize with iNOS RNA and thereby inhibit the synthesis of iNOS. Hybridization occurs when an antisense oligonucleotide effectively binds to a target iNOS mRNA so that a reduction occurs in the synthesis of the iNOS protein.
- the inhibition of iNOS synthesis occurs because of steric hindrance of macromolecular translating mechanism and/or the activation of RNAase enzymes. Inhibition of the synthesis of iNOS reduces the production of nitric oxide, thus lessening damage to the lungs caused by the toxicity of NO. This allows patients to recover more easily and with less morbidity and mortality from a viral influenza infection.
- the present invention also includes pharmaceutical compositions comprising an effective amount of at least one iNOS inhibiting antisense oligonucleotide in a pharmaceutical vehicle that can effectively deliver the oligonucleotide to the lung.
- the method of the present invention will be utilized in patient treatment as long as it is necessary to reduce the inflammatory effects of iNOS on the lungs resulting from an influenza infection.
- One of skill in the art will be able to optimize the starting point and treatment duration of the present invention. For example, treatment can begin immediately at the time symptoms of influenza are detected and end within a week or two after the symptoms of influenza subside.
- Effectiveness of an influenza treatment can be demonstrated clinically by methods well known to one of ordinary skill in the art. Such methods include observation of improvement in a patient's symptoms or samples of lung tissue taken through an endoscope. Signs of recovery from influenza include defervescence, improved respiration, reduced cough and sputum, and an increased appetite. The duration of the iNOS antisense therapy will generally last until the patient has recovered from influenza. This will most often be at least one week after the onset of infection, with treatment optionally continuing for several weeks.
- Nitric oxide is defined herein as an inorganic radical produced by different isoforms of NO synthase (NOS).
- NOS NO synthase
- Nitric oxide or NO is also used herein to collectively refer to the reactive intermediates of nitric oxide and oxygen and water such as other radicals (e.g. NO 2 ), anions (e.g. NO2 “ or NO3 " ), higher oxides (e.g. N2O3) and peroxides (ONOO ).
- NO At nanomolar concentrations, NO regulates many physiological processes. At higher levels, however, NO is cytotoxic. Viral influenza infection increases peroxynitrate in murine lung tissue. Akaike, et al , Proc. Nat'l Acad. Sci. U SA, 93: 2448 (1996). This may account for the destruction of lung tissue during a viral influenza infection because peroxynitrate is a highly cytotoxic agent in lung tissue. Wizemann, et al., J. Leukoc.
- the present invention employs an antisense oligonucleotide that is targeted to mRNA associated with inducible nitric oxide synthase.
- mRNA includes not only the coding or translated region, which carries the information to encode a protein using the three letter genetic code, but also associated ribonucleotides that form the 3' and 5 '-untranslated region, including the 5 '-cap region.
- oligonucleotides may preferably be formulated which are targeted wholly or in part to these associated ribonucleotides.
- Antisense oligonucleotides have already been used to inhibit human iNOS.
- the present invention also contemplates the use of other antisense oligonucleotide sequences that have been used to inhibit human iNOS.
- suitable antisense oligonucleotides can be selected empirically for the present invention.
- a suitable antisense oligonucleotide can be designed to target a translation initiation site (the AUG start codon) and/or sites that are close to the initiation site, such as those that are within about 20 bases of the AUG start codon.
- the antisense oligonucleotide is targeted to nucleotides that include the 5' untranslated region of the iNOS mRNA.
- Antisense oligonucleotides can be targeted to the 5' untranslated region and the initiation site, to the translated region and the initiation site, or to a combination of the 5' untranslated region, the initiation site and the translated region.
- the antisense oligonucleotide is targeted to a site on the mRNA molecule that contains regions that are accessible to hybridization with an antisense oligonucleotide.
- the secondary and tertiary structure adopted by mRNA molecules leaves only a few sequence stretches accessible to hybridization with antisense mRNA. Such accessible sites can lie in the translated region, the untranslated region or both regions.
- the functions of the RNA that are to be interfered with or inhibited include all vital functions, such as translocation of the RNA to the site for protein translation, actual translation of protein from the RNA, splicing or maturation of the RNA, and possibly even independent catalytic activity.
- the overall effect of such interference with the RNA function is to interfere or inhibit iNOS protein expression, and thereby reducing the synthesis of nitric oxide.
- hybridization means hydrogen bonding between complementary bases, also known as Watson-Crick base pairing, usually on opposite nucleic acid strands or two regions of a nucleic acid strand.
- Guanine and cytosine are examples of complementary bases that are known to form three hydrogen bonds between one another.
- Adenine and thymine or adenine and uracil are examples of complementary bases that form two hydrogen bonds between them.
- the phrases “specifically hybridizable” and “specifically hybridizes” indicate that stable, specific binding occurs between the RNA target and the antisense oligonucleotide. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable.
- An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the previously uninfluenced function of the target molecule, causing a loss of its effectiveness while tending to avoid non-specific binding to non-target sequences.
- an antisense oligonucleotide To select the preferred length for an antisense oligonucleotide, a balance should be struck to gain the most favorable characteristics. Shorter oligonucleotides 6-15 bases in length readily enter cell, but have lower specificity. In contrast, longer oligonucleotides of 20-32 bases are more specific, but show decreased kinetics of uptake into the cell. In a preferred embodiment this invention uses oligonucleotides from about 7 to about 32 nucleotides long. Because in the present invention antisense mRNA is administered directly to the lungs, specificity of the oligonucleotides is less of a concern than if the oligonucleotides were to be administered systemically.
- Figure 1 Illustrated in Figure 1 is the sequence of a cDNA produced from a human iNOS mRNA obtained from airway epithelium. See also Proc. Nat'l Acad. Sci. U.S.A. 92: 7809 (1995) (Genbank accession number U20141).
- Figure 2 includes the 5 '-untranslated region of the cDNA of human iNOS mRNA, as published in J. Mol. Cell Cardiol. 29 (4) 1,153- 65 (1997) (Genbank accession number AF068236).
- influenza refers to all viral types of influenza, including influenza A, influenza B, and influenza C.
- influenza A refers to all viral types of influenza, including influenza A, influenza B, and influenza C.
- influenza B Preparation of Antisense Oligonucleotides
- oligonucleotide and antisense oligonucleotide denote oligomers both of a ribonucleotide, and oligomers of deoxyribonucleotide. Oligodeoxynucleotides are preferred.
- oligonucleotide also includes oligomers that may be large enough to be “polynucleotides.”
- oligonucleotide and “antisense oligonucleotide” include not only oligomers and polymers of the common biologically significant nucleotides, i.e., the nucleotides adenine ("A"), deoxyadenine ("dA”), guanine (“G”), deoxyguanine (“dG”), cytosine ("C”), deoxycytosine (“dC”), thymine (“T”) and uracil (“U”), but also include oligomers and polymers hybridizable to the iNOS mRNA transcript, such as 5- propynyluracil, 5-methylcytsine, 5-propynylcytosine, and 2-aminoadenine.
- Oligonucleotide and “antisense oligonucleotide” also denote oligomers and polymers wherein one or more purine or pyrimidine moieties, sugar moieties or internucleotide linkages are synthetically modified. This includes oligonucleotides having portions wherein at least one building block of the oligonucleotide differs from the building blocks of a natural oligonucleotide such as wherein the sugar moieties and/or inter-sugar linkages are modified.
- the bases may also be modified to increase binding properties such as duplex or triplex stability, specificity, or the like, as described, for example, by Scheit, NUCLEOTIDE ANALOGS (John Wiley, New York, 1980).
- oligonucleotide derivatives in which the internucleotide phosphodiester bond has been modified.
- the present invention contemplates the use of all such oligonucleotides, so long as they are capable of binding to nucleic acids found in nature.
- Modifications to the phosphate backbone include other species such as phosphorodithioate, sulfate, sulfonate, sulfonamide, sulfone, sulfite, sulf oxide, sulfide, formacetal, 3'-thioformacetal, 5'-thioether, see International Application WO 92/20823), morpholino-carbamate (see U.S. patent No: 5,034,506) or peptide nucleic acids, (see Nielsen et al , Science 254: 1497 (1991)) which are known for use in the art. For reviews concerning these modified nucleotides, see Milligan et al, J. Med. Chem.
- At least one of the phosphodiester bonds of the oligonucleotide has been substituted with a structure that functions to enhance the ability of the compositions to penetrate into the region of cells where the mRNA to be hybridized to is located. This avoids extensive degradation of the oligonucleotide derivative by nucleases, which would result in ineffective products.
- substitutions comprise phosphorothioate bonds, phosphorodithioate bonds, methyl phosphonate bonds, phosphoramidate bonds, amide bonds, boranophosphate bonds, phosphotriester bonds, short chain alkyl or cycloalkyl structures, or heteroatom-substituted short chain alkyl structures, and most especially phosphorothioate bonds or methyl phosphonate bonds.
- substitutions comprise phosphorothioate bonds, phosphorodithioate bonds, methyl phosphonate bonds, phosphoramidate bonds, amide bonds, boranophosphate bonds, phosphotriester bonds, short chain alkyl or cycloalkyl structures, or heteroatom-substituted short chain alkyl structures, and most especially phosphorothioate bonds or methyl phosphonate bonds.
- Persons knowledgeable of this field will be able to select other linkages for use in the present invention.
- Oligonucleotides can be conjugated with synthetic polypeptides such as poly-L-lysine, or with acridine, cholesterol, and poly-rA. Liposomes, especially those involving cationic lipids, have been use extensively to enhance the uptake of antisense oligonucleotides.
- a preferred embodiment of the present invention employs cationic lipids such as N-[l(-2,3- dioleyloxy)propy]-N,N,N-trimethylammonium chloride (DOTMA) (available from Gibco BRL as Lipofectin ® ), dimethyldictadecylammonium bromide (DDAB) or N, N, N', N'- tetramethyl-N, N'-bis [2-hydroxyethyl]-2,3-dioleoyloxy-l, 4-butanediammonium iodide (available from Promega as Tfx-10).
- DOTMA N-[l(-2,3- dioleyloxy)propy]-N,N,N-trimethylammonium chloride
- DDAB dimethyldictadecylammonium bromide
- any of the well-known methods of delivering D ⁇ A to the lungs can be used with the present invention.
- methods for the gene therapy of cystic fibrosis have been extensively researched. See Wheeler et al, Proc. Nat'l Acad. Sci. USA 93: 1454 (1996).
- cationic lipids such as (+)-N-(3- an ⁇ onpropyl)-N,N-dimemyl-2,3-bw(dodecyloxy)-l-propanaminium bromide (GAP- DLRIE), could be used to deliver antisense oligonucleotides.
- GAP- DLRIE cationic lipids
- Antisense oligonucleotides can be encapsulated within liposomes using standard techniques. Those of skill in the art know a variety of different liposome compositions and methods of synthesis. See, for example, U.S. patents No. 4,844,904, No. 5,000,959, No. 4,863,740, and No. 4,975,282. Liposomes can be targeted to particular cells by varying phospholipid composition or by inserting target-specific receptors or ligands into the liposomes.
- Another potential form of packaging would be to freeze dry the antisense oligonucleotide, and suitably package it in a dry powder, such as lactose.
- This formulation would facilitate inhalation in conjunction with other medicines or compounds formulated for dry powder inhalation, e.g. zanamir. It is contemplated that some combination of dry powder and liposome may also be a successful formulation for topical intrapulmonary administration.
- the dosage of administered oligonucleotides will vary, depending upon such factors as the patient's age, weight, height, sex, general medical condition, and previous medical history. Dose ranges for particular formulations can be determined by resort to a suitable animal model and clinical trials. Dosage amounts of the present invention include, but are not limited to, from about .01 to about 50 mg/kg of vehicle with a pharmaceutically effective amount of antisense oligonucleotides administered to the lungs as a dry powder or aerosol. Another embodiment includes a range from about .1 to about 10 mg/kg.
- the antisense oligonucleotides of the present invention can be applied to the lungs with varying frequency and for varying duration. In this regard, the skilled artisan will appreciate how to alter the frequency and duration of application to achieve the desired effect. For example, the antisense oligonucleotides of the instant invention can be taken at varying frequencies, including one or more times daily. Again, the skilled artisan will appreciate the interaction between frequency and duration of use in order to achieve and/or maintain the desired effect.
- the skilled artisan will appreciate how to vary concentrations of the instant invention in conjunction with the frequency and duration of use to achieve the desired effect.
- concentrations of the instant invention in conjunction with the frequency and duration of use to achieve the desired effect.
- the antisense oligonucleotides in a composition of higher concentration or a slow-release formulation might be applied with less frequency or for a shorter duration.
- antisense oligonucleotides of a lower concentration might be applied more frequently or for a longer duration.
- IFN ⁇ with 0, 2, 5, or 10 ⁇ M of antisense.
- Sense and mixed oligonucleotides i.e., the same nucleotides as in antisense, but in random order
- the efficacy is preferably measured by NO production. Dose response can also be measured by observing NOS activity and the relationship between iNOS mRNA and
- iNOS antisense therapy increases the survival chances from an influenza infection.
- One preferred animal model is influenza-challenged mice. Virus is prepared in eggs and viral titer is determined using MDCK cells. Animals are then inoculated with influenza to determine the lethal dose at which 50% and 90% of the animals die (LD50 and
- LD50 or LD90 of influenza are administered using nebulization or tracheal injection on a daily basis. The survival rate is noted and samples are taken to evaluate lung histopathology. Additionally, plaque-forming units (PFU) can be quantified to determine viral burden.
- PFU plaque-forming units
- NO/NOS in influenza infected animals can be measured with numerous methods.
- One such method is to measure NO production in lung by various methods including a MGD spintrap, Greiss reagent, or fluorometer.
- NOS activity can be measured by L-[ 14 C] arginine conversion and
- NOS mRNA levels by Northern blotting.
- Metabolic byproducts of NO, such as peroxynitrite or nitrotyrosine can be measured by spintraps or antibodies, respectively.
- Outcome measures include standard toxicity measures such as weight change, general gross and histologic pathology, the pulmonary histology post-infection studies, the pulmonary weight and appearance at specified intervals post-infection, and survival.
- iNOS antisense as a prophylaxis or a treatment can be optimized in various ways.
- the timing of administration can be optimized by pre-inoculation treatment, simultaneous inoculation and treatment, and post-inoculation treatment.
- Various formulations and methods of administration known to one of ordinary skill in the art can also be used to optimize the in vivo application of the present antisense oligonucleotides.
- formulations include the previously discussed cationic lipids and liposomes.
- Methods of administration include administration by a pressurized meter dose inhaler, such as the kinds used to deliver drugs to treat asthma therapies, or nebuliziers that deliver aerosols by compression or ultrasonic means, as well as inhalation of powder.
- Effectiveness of an influenza treatment can be demonstrated clinically by methods well known to one of ordinary skill in the art. Such methods include observation of improvement in a patient's symptoms or samples of lung tissue taken with for an endoscope. Signs of recovery from influenza include a reduction in fever, improved respiration, increased production of sputum, and an increased appetite.
- the duration of the iNOS antisense therapy will generally last until the patient has recovered from the influenza infection and its complications. This will often be one week after the onset of infection, with treatment optionally continuing for several weeks.
- antisense oligonucleotides can be administered with zanamivir or another antiviral, with a steroids such as beclamethasone, for example, or with a combination of an antiviral and a steroid drug.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63360/00A AU6336000A (en) | 1999-06-17 | 2000-06-19 | Treatment of viral influenza with antisense oligonucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13947999P | 1999-06-17 | 1999-06-17 | |
US60/139,479 | 1999-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000078946A2 true WO2000078946A2 (en) | 2000-12-28 |
WO2000078946A3 WO2000078946A3 (en) | 2001-05-03 |
Family
ID=22486862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/016810 WO2000078946A2 (en) | 1999-06-17 | 2000-06-19 | Treatment of viral influenza with antisense oligonucleotides |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6336000A (en) |
WO (1) | WO2000078946A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
-
2000
- 2000-06-19 WO PCT/US2000/016810 patent/WO2000078946A2/en active Application Filing
- 2000-06-19 AU AU63360/00A patent/AU6336000A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040162A1 (en) * | 1995-06-07 | 1996-12-19 | East Carolina University | Method of treatment for lung diseases using antisense oligonucleotides |
Non-Patent Citations (5)
Title |
---|
AKAIKE TAKAAKI ET AL: "Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 6, 1996, pages 2448-2453, XP002156507 ISSN: 0027-8424 * |
ARIMA HIDETOSHI ET AL: "Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides." JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 86, no. 10, 1997, pages 1079-1084, XP002156509 ISSN: 0022-3549 * |
KARUPIAH GUNASEGARAN ET AL: "Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 8, 19 October 1998 (1998-10-19), pages 1541-1546, XP002156508 ISSN: 0022-1007 * |
MAEDA HIROSHI ET AL: "Multiple functions of nitric oxide in pathophysiology and microbiology: Analysis by a new nitric oxide scavenger." JOURNAL OF LEUKOCYTE BIOLOGY, vol. 56, no. 5, 1994, pages 588-592, XP000971906 ISSN: 0741-5400 * |
SELLERI CARMINE ET AL: "Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells." BRITISH JOURNAL OF HAEMATOLOGY, vol. 99, no. 3, 1 December 1997 (1997-12-01), pages 481-489, XP000971900 ISSN: 0007-1048 cited in the application * |
Also Published As
Publication number | Publication date |
---|---|
WO2000078946A3 (en) | 2001-05-03 |
AU6336000A (en) | 2001-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3103872T3 (en) | OLIGONUCLEOTIDES TO MAKE A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE IN A LIVING CELL | |
US5994315A (en) | Low adenosine agent, composition, kit and method for treatment of airway disease | |
US8501188B2 (en) | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides | |
Li et al. | Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors | |
EP0894129B1 (en) | Short external guide sequences | |
EP0831924A1 (en) | Method of treatment for asthma | |
WO1998023294A9 (en) | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation | |
CA2272900A1 (en) | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation | |
JP2001518292A (en) | Nucleic acid catalyst having endonuclease activity | |
WO2003008628A2 (en) | Enzymatic nucleic acid peptide conjugates | |
JP2007523658A (en) | Substances and methods for treating allergic diseases | |
US6566514B1 (en) | Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth | |
WO2000078946A2 (en) | Treatment of viral influenza with antisense oligonucleotides | |
EP1766013B1 (en) | Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases | |
CA2302167A1 (en) | Antisense treatment of pulmonary hypertension | |
AU699330C (en) | Method of treatment for asthma | |
AU724817B2 (en) | Method of treatment for asthma | |
Ge et al. | Pulmonary delivery of small interfering RNA for novel therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |